China’s National Medical Products Administration (NMPA) approves Padcev in combination with Keytruda (Pembrolizumab) for the treatment of advanced bladder cancer

CAR-T Digest - August 2020

Weekly Digest - January 2025

08 Jan 2025: China’s National Medical Products Administration (NMPA) approves Padcev in combination with Keytruda (Pembrolizumab) for the treatment of advanced bladder cancer

China’s NMPA has approved enfortumab vedotin in combination with pembrolizumab as a first-line treatment for adult patients with locally advanced or metastatic urothelial cancer, offering an alternative to platinum-based chemotherapy
The Phase 3 EV-302 (KEYNOTE-A39) clinical trial demonstrated that the combination therapy significantly improved median overall survival (31.5 months vs. 16.1 months) and progression-free survival (12.5 months vs. 6.3 months) compared to platinum-based chemotherapy
The approval of the first non-platinum first-line treatment for advanced urothelial cancer in China is set to transform the treatment landscape